Home » FDA Needs More Time to Review Bristol-Myers’s Ipilimumab
FDA Needs More Time to Review Bristol-Myers’s Ipilimumab
Drug maker Bristol-Myers Squibb Co. said the U.S. Food and Drug Administration needs additional time to finish a review of the license application for the company’s melanoma treatment, pushing back its decision date by three months.
ADVFN
ADVFN
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May